About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Vhltm1.1Lss
targeted mutation 1.1, Laura S Schmidt
MGI:2677579
Summary 5 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
ht1
Vhltm1.1Lss/Vhl+ involves: A/J MGI:2677768
ht2
Vhltm1.1Lss/Vhl+ involves: BALB/c MGI:2677767
ht3
Vhltm1Lss/Vhltm1.1Lss involves: 129X1/SvJ * C57BL/6 MGI:2677761
cn4
Vhltm1Lss/Vhltm1.1Lss
Tg(CAG-cre/Esr1*)1Lbe/0
involves: 129S1/Sv * 129X1/SvJ MGI:3653510
cn5
Vhltm1Lss/Vhltm1.1Lss
Tg(ACTB-cre)1Tes/0
involves: 129X1/SvJ * C3H * C57BL/6 MGI:2677759


Genotype
MGI:2677768
ht1
Allelic
Composition
Vhltm1.1Lss/Vhl+
Genetic
Background
involves: A/J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Vhltm1.1Lss mutation (0 available); any Vhl mutation (6 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
liver/biliary system
• 66% showed hepatic vascular lesions on a A/J genetic background

Mouse Models of Human Disease
OMIM ID Ref(s)
Von Hippel-Lindau Syndrome; VHL 193300 J:85513




Genotype
MGI:2677767
ht2
Allelic
Composition
Vhltm1.1Lss/Vhl+
Genetic
Background
involves: BALB/c
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Vhltm1.1Lss mutation (0 available); any Vhl mutation (6 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
liver/biliary system
• 88% showed hepatic hemangiomas by 18 months of age, on a BALB/c genetic background

neoplasm
• 88% showed hepatic hemangiomas by 18 months of age, on a BALB/c genetic background

Mouse Models of Human Disease
OMIM ID Ref(s)
Von Hippel-Lindau Syndrome; VHL 193300 J:85513




Genotype
MGI:2677761
ht3
Allelic
Composition
Vhltm1Lss/Vhltm1.1Lss
Genetic
Background
involves: 129X1/SvJ * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Vhltm1.1Lss mutation (0 available); any Vhl mutation (6 available)
Vhltm1Lss mutation (0 available); any Vhl mutation (6 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
liver/biliary system
• observed in 18% of mice between 4 and 12 months of age, putatively due to sporadic LOH
• smaller than those observed in Vhlhtm1Lss/ Vhlhtm1.1Lss;Tg(ACTB-cre)1Tes mice

neoplasm
• observed in 18% of mice between 4 and 12 months of age, putatively due to sporadic LOH
• smaller than those observed in Vhlhtm1Lss/ Vhlhtm1.1Lss;Tg(ACTB-cre)1Tes mice

reproductive system
• 2-fold reduction in sperm count relative to wild-type

Mouse Models of Human Disease
OMIM ID Ref(s)
Von Hippel-Lindau Syndrome; VHL 193300 J:85513




Genotype
MGI:3653510
cn4
Allelic
Composition
Vhltm1Lss/Vhltm1.1Lss
Tg(CAG-cre/Esr1*)1Lbe/0
Genetic
Background
involves: 129S1/Sv * 129X1/SvJ
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(CAG-cre/Esr1*)1Lbe mutation (0 available)
Vhltm1.1Lss mutation (0 available); any Vhl mutation (6 available)
Vhltm1Lss mutation (0 available); any Vhl mutation (6 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• all embryos of pregnant females injected with 2 mg of tamoxifen at E10.5 to inactive Vhlh during mid-gestational stage, die between E14.5 and E15.5

growth/size/body
• embryos of pregnant females injected with tamoxifen at E10.5 are smaller than controls

cardiovascular system
• treatment of pregnant females at E10.5 with tamoxifen results in abnormal vasculature and dilated blood vessels in the body of E14.7 embryos
• dilated vessels are frequently seen after tamoxifen treatment
• treatment of pregnant females at E10.5 with tamoxifen results in impaired blood circulation in the yolk sac of E14.7 embryos
• treatment of pregnant females at E10.5 with tamoxifen results in hemorrhage in the dorsolateral region of embryos at E14.5

cellular
• at 24 hrs after bilateral renal ischemia-reperfusion injury (IRI), tamoxifen-treated mice exhibit significantly fewer TUNEL+ cells in the proximal tubules relative to tamoxifen-treated control mice

embryo
• treatment of pregnant females at E10.5 with tamoxifen results in impaired blood circulation in the yolk sac of E14.7 embryos
• embryos of pregnant females injected with tamoxifen at E10.5 are smaller than controls
• treatment of pregnant females at E10.5 with tamoxifen results in extensive embryo necrosis
• when pregnant females are injected with tamoxifen at E10.5, frequently observe dilated blood vessels and spongiotriophoblast cells in the labyrinthine layer
• dilated vessels are frequently seen after tamoxifen treatment
• thickness of the labyrinthine layer is reduced when pregnant females are injected with tamoxifen at E10.5

liver/biliary system
• treatment of pregnant females at E10.5 with tamoxifen results in focal necrosis in the liver or E14.5 embryos

integument
• seen in embryos of pregnant females injected with tamoxifen at E10.5

homeostasis/metabolism
• at 24 hrs after bilateral renal ischemia-reperfusion injury (IRI), tamoxifen-treated mice exhibit significantly lower serum creatinine levels than tamoxifen-treated control mice (0.24 +/- 0.04 mg/dl versus 0.72 +/- 0.16 mg/dL, respectively)
• at 24 hrs after bilateral renal IRI, tamoxifen-treated mice exhibit significantly lower serum BUN levels than tamoxifen-treated control mice (52.12 +/- 6.61 mg/dl versus 138.10 +/- 13.03 mg/dL, respectively)
• at 24 hrs after bilateral renal IRI, tamoxifen-treated mice (0.36mg/g body weight injected i.p. one wk prior to IRI) exhibit better preservation of renal function and significantly lower tubular injury scores than tamoxifen-treated control mice (2.40 +/- 0.08 and 0.90 +/- 0.12, respectively), consistent with reduced proximal tubular injury, near absence of TUNEL+ cells, and milder tubular epithelial degeneration

renal/urinary system
• at 24 hrs after bilateral renal ischemia-reperfusion injury (IRI), tamoxifen-treated mice exhibit significantly fewer TUNEL+ cells in the proximal tubules relative to tamoxifen-treated control mice
• at 24 hrs after bilateral renal IRI, tamoxifen-treated mice (0.36mg/g body weight injected i.p. one wk prior to IRI) exhibit better preservation of renal function and significantly lower tubular injury scores than tamoxifen-treated control mice (2.40 +/- 0.08 and 0.90 +/- 0.12, respectively), consistent with reduced proximal tubular injury, near absence of TUNEL+ cells, and milder tubular epithelial degeneration




Genotype
MGI:2677759
cn5
Allelic
Composition
Vhltm1Lss/Vhltm1.1Lss
Tg(ACTB-cre)1Tes/0
Genetic
Background
involves: 129X1/SvJ * C3H * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(ACTB-cre)1Tes mutation (0 available)
Vhltm1.1Lss mutation (0 available); any Vhl mutation (6 available)
Vhltm1Lss mutation (0 available); any Vhl mutation (6 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• mice began to die after 3 months of age
• 50% mortalitiy exhibited by 7 months of age
• 90% mortalitiy by 1 year of age

neoplasm
• all mice displayed grossly visible hemangiomas by 1 year of age

cardiovascular system
• frequent angiectasis in the liver and with lesser penetrance in the kidneys
• increased vasculature of the pancreas
• no vascular lesions observed in the brain, ovary, or adrenal glands
• limited new blood vessel formation in the liver
• angiogenesis observed the cardiac muscle of 8 of 10 mice examined

endocrine/exocrine glands
• enlarged blood vessels in the connective tissue surrounding the tubules
• tubule atrophy and collapse

liver/biliary system
• livers were irregularly shaped and had vascular lesions containing large, thin-walled vessels filled with blood
• all mice displayed grossly visible hemangiomas by 1 year of age

reproductive system
• enlarged blood vessels in the connective tissue surrounding the tubules
• tubule atrophy and collapse
• abnormal sperm maturation with multinucleated giant cells
• 30-fold reduction in sperm count relative to wild-type

Mouse Models of Human Disease
OMIM ID Ref(s)
Von Hippel-Lindau Syndrome; VHL 193300 J:85513





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Tumor Biology (MTB), Gene Ontology (GO), MouseCyc
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
07/19/2016
MGI 6.04
The Jackson Laboratory